Astra and Pozen's Vimovo gets EU approval

11th Oct 2010 07:08

Drugs companies AstraZeneca and Pozen said their jointly developed pain reliever Vimovo has received positive agreement for approval across 23 EU countries.Vimovo has been developed for the symptomatic treatment of osteoarthritis, rheumatoid arthritis, and ankylosing spondylitis in patients who are at risk for developing non-steroidal anti-inflammatory drug (NSAID) associated gastric and/or duodenal ulcers.The latest milestone for the drug results in a harmonised Summary of Product Characteristics and allows the drug developers to pursue pricing and reimbursement and national approvals."This support for the approval of Vimovo in Europe is a significant milestone, which we believe will provide a new treatment option for the millions of arthritis patients in the EU at risk for NSAID-associated ulcers," said Lori Kreamer, Global Products Vice President, AstraZeneca. "In one tablet, VIMOVO offers the proven pain relief of naproxen with built-in ulcer risk reduction," Kreamer added.